Haemate P

Haemate P is a prescription intravenous concentrate containing human coagulation factor VIII and von Willebrand factor. It is supplied as a sterile solution for intravenous infusion. The product is marketed in the European Union and is classified as a factor VIII/VWF concentrate used to replace deficient clotting proteins. It is indicated for patients with hemophilia A or von Willebrand disease who require prophylactic or on‑demand treatment to achieve hemostasis.

Haemate P is used to manage bleeding disorders that involve deficiency of factor VIII, von Willebrand factor, or both.

- Prophylactic replacement therapy in patients with severe hemophilia A to prevent spontaneous joint and muscle bleeds. - On‑demand treatment of acute bleeding episodes in hemophilia A. - Management of bleeding episodes and surgical prophylaxis in patients with von Willebrand disease types 1, 2, and 3. - Peri‑operative hemostatic coverage for surgical or invasive procedures in individuals with combined factor VIII and VWF deficiency. - Supportive therapy in patients undergoing major trauma when factor levels are low.

Adverse reactions reported with Haemate P vary in frequency and severity.

Common: - Mild headache or fatigue, typically transient and not requiring specific treatment. - Low-grade fever or chills occurring shortly after infusion, usually resolving within 24 hours. - Local infusion site reactions such as erythema, mild pain, or swelling at the catheter site.

Serious: - Development of inhibitors (neutralizing antibodies) to factor VIII, which can reduce treatment efficacy and may require alternative therapies. - Severe allergic reactions, including urticaria, bronchospasm, or anaphylaxis, necessitating immediate medical intervention. - Thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, particularly in patients with pre‑existing risk factors.

When prescribing Haemate P, clinicians should consider several precautionary measures to ensure safe and effective use.

- Test for factor VIII inhibitors before initiating therapy and periodically during treatment. - Assess for a history of allergic reactions to plasma‑derived products. - Use caution in patients with a history of thrombosis or cardiovascular disease. - Monitor for signs of infection, especially if the product is administered via a central line. - Adjust dosage in patients with renal or hepatic impairment as recommended by clinical guidelines. - Avoid use in patients with known hypersensitivity to any component of the formulation.

Haemate P may interact with other medications that affect hemostasis or immune response.

Avoid: - Concomitant use of other factor concentrates or bypassing agents without specialist guidance, as this may increase thrombotic risk. - Administration with high‑dose aspirin or non‑steroidal anti‑inflammatory drugs (NSAIDs) that impair platelet function.

Use with caution: - Antifibrinolytic agents such as tranexamic acid, which can augment clot stability when used together. - Immunosuppressive therapies that may alter inhibitor development. - Vaccinations administered shortly before or after infusion, which could affect immune response. - Heparin or low‑molecular‑weight heparin, requiring careful monitoring of anticoagulation parameters.